Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023)

Historic Capital Expenditures for Marker Therapeutics (MRKR) over the last 6 years, with Q1 2023 value amounting to $141979.0.

  • Marker Therapeutics' Capital Expenditures fell 9390.26% to $141979.0 in Q1 2023 from the same period last year, while for Mar 2023 it was -$2.1 million, marking a year-over-year decrease of 14986.8%. This contributed to the annual value of $57607.0 for FY2022, which is 9733.4% down from last year.
  • Per Marker Therapeutics' latest filing, its Capital Expenditures stood at $141979.0 for Q1 2023, which was down 9390.26% from -$24691.0 recorded in Q4 2022.
  • In the past 5 years, Marker Therapeutics' Capital Expenditures registered a high of $2.5 million during Q2 2020, and its lowest value of -$2.3 million during Q2 2022.
  • Over the past 5 years, Marker Therapeutics' median Capital Expenditures value was $66170.0 (recorded in 2022), while the average stood at $236041.8.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 123358.37% in 2020, then crashed by 374178.6% in 2022.
  • Quarter analysis of 5 years shows Marker Therapeutics' Capital Expenditures stood at -$223126.0 in 2019, then crashed by 220.28% to -$714619.0 in 2020, then skyrocketed by 392.51% to $2.1 million in 2021, then plummeted by 101.18% to -$24691.0 in 2022, then soared by 675.02% to $141979.0 in 2023.
  • Its Capital Expenditures stands at $141979.0 for Q1 2023, versus -$24691.0 for Q4 2022 and $66170.0 for Q3 2022.